{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:15:35Z","timestamp":1773947735262,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015728","name":"Clinical Science Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.014","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:53Z","timestamp":1749770153000},"page":"450-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Evolving Management of Radiorecurrent Prostate Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Jacob","family":"Pozin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menal","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia C.","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juanita","family":"Crook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley L.","family":"Liauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Harkenrider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2186-2987","authenticated-orcid":false,"given":"Abhishek A.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semradonc.2025.04.014_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.014_bib0002","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO Guideline part III: Salvage therapy after radiotherapy or Focal therapy, Pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0003","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00345-024-05205-9","article-title":"Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy","volume":"42","author":"Saripalli","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0004","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2012.00048","article-title":"Management of biochemical recurrence after primary localized therapy for prostate cancer","volume":"2","author":"Darwish","year":"2012","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/dir.2018.17285","article-title":"Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy","volume":"24","author":"Valle","year":"2018","journal-title":"Diagn Interv Radiol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.rcl.2017.10.008","article-title":"Prostate MR imaging for posttreatment evaluation and recurrence","volume":"56","author":"Gaur","year":"2018","journal-title":"Radiol Clin North Am"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00261-008-9495-2","article-title":"Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience","volume":"35","author":"Kim","year":"2010","journal-title":"Abdom Imaging"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.014_bib0008","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"issue":"10231","key":"10.1016\/j.semradonc.2025.04.014_bib0009","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen pet-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (propsma): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0010","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.semradonc.2025.04.014_bib0011","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR Phase III, Multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"10288","key":"10.1016\/j.semradonc.2025.04.014_bib0013","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.014_bib0014","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ijrobp.2022.12.055","article-title":"PSMA-PET\/CT-guided intensification of radiation therapy for prostate cancer (PSMAgRT): findings of detection rate, effect on cancer management, and early toxicity from a phase 2 randomized controlled trial","volume":"116","author":"Petit","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.014_bib0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0016","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: Treatment based on risk stratification","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"32","key":"10.1016\/j.semradonc.2025.04.014_bib0017","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0018","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations","volume":"6","author":"Van den Broeck","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.014_bib0019","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.014_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: A pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.014_bib0021","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3390\/diagnostics12112594","article-title":"PSMA PET-CT in the diagnosis and staging of prostate cancer","volume":"12","author":"Combes","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","article-title":"PSMA PET\/CT for primary staging of prostate cancer - an updated overview","volume":"54","author":"Jochumsen","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"supplement 2","key":"10.1016\/j.semradonc.2025.04.014_bib0023","first-page":"3041","article-title":"Kinetics and patterns of PSMA pet uptake after radiation therapy for prostate cancer: A single center retrospective study","volume":"63","author":"Hotta","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2022.02.014","article-title":"Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: Implications for potential salvage","volume":"169","author":"Maitre","year":"2022","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.014_bib0025","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.euo.2020.01.002","article-title":"Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix criteria for biochemical recurrence after curative radiotherapy","volume":"4","author":"Jansen","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.014_bib0026","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ijrobp.2023.02.039","article-title":"Patterns of failure in men with radiorecurrent prostate cancer: A post hoc analysis of 3 prospective gallium 68 prostate-specific membrane antigen positron emission tomography\/computed tomography imaging trials","volume":"116","author":"Smith","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0027","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2018.09.039","article-title":"A prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology\/RTOG-0526)","volume":"103","author":"Crook","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0028","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0029","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2214\/AJR.22.28665","article-title":"PI-RR: the Prostate imaging for recurrence reporting system for MRI assessment of local prostate cancer recurrence after radiation therapy or radical prostatectomy-A review","volume":"220","author":"Abreu-Gomez","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0030","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate Magnetic resonance imaging for local recurrence reporting (PI-RR): International consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0031","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00259-020-04945-1","article-title":"False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial","volume":"48","author":"Fendler","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.02.042","article-title":"The importance of multi-parametric MRI, PET\/CT, and biopsy for identifying and delineating the extent of intraprostatic radiorecurrent prostate cancer: A secondary analysis of the F-SHARP clinical trial","author":"Venkatesulu","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0033","doi-asserted-by":"crossref","unstructured":"Solanki A, Proudfoot J, Adamset W, et al: Decipher risk stratification of radiorecurrent prostate cancer: correlative analysis of the F-SHARP trial of salvage reirradiation, Am Soc Clin Oncol, 43, (suppl 5; abstr 419)2025. https:\/\/www.meetings.asco.org\/abstracts-presentations\/242248.","DOI":"10.1200\/JCO.2025.43.5_suppl.419"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2024.42.4_suppl.15","article-title":"Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study","volume":"42","author":"Shore","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0035","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.23.01157","article-title":"A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0036","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with No metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.014_bib0037","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy [published correction appears in N Engl J Med. 2012 Dec 6;367(23):2262]","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.014_bib0038","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs continuous Androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncology"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.014_bib0039","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol."},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.014_bib0041","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.adro.2020.04.022","article-title":"A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: systematic review and meta-analysis","volume":"5","author":"Corkum","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0042","article-title":"MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer [published correction appears in Front Oncol. 2022 Nov 17;12:1084708. doi: 10.3389\/fonc.2022.1084708.]","volume":"12","author":"M\u00e9nard","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0043","article-title":"Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation","volume":"48","author":"Meraouna","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0044","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2019.10.014","article-title":"Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-like SBRT","volume":"106","author":"Fuller","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: a phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy\u2014Study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0046","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"The safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: phase 1 results from the GETUG-AFU 31 study","volume":"6","author":"Pasquier","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0047","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.clgc.2023.01.007","article-title":"Early safety and efficacy profile of homogeneously dosed salvage stereotactic body radiotherapy (SBRT) for intraprostatic recurrences after low dose rate (LDR) brachytherapy","volume":"21","author":"Nikitas","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0048","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.brachy.2017.07.013","article-title":"Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time","volume":"16","author":"Kollmeier","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0049","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.radonc.2019.09.006","article-title":"Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy","volume":"141","author":"Henr\u00edquez L\u00f3pez","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.861127","article-title":"A prospective study of high dose-rate brachytherapy or stereotactic body radiotherapy of intra-prostatic recurrence: toxicity and long term clinical outcome","volume":"12","author":"Ryg","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0051","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13014-017-0789-9","article-title":"Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy","volume":"12","author":"Mbeutcha","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068580","article-title":"Reirradiation options for previously irradiated prostate cancer (RO-PIP): feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)","volume":"12","author":"Zhong","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.014_bib0053","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.euo.2023.03.005","article-title":"Salvage stereotactic reirradiation for local recurrence in the prostatic bed after prostatectomy: A retrospective multicenter study","volume":"6","author":"Archer","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0054","article-title":"European Association of Urology Risk Stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy. Radiotherapy and oncology","volume":"194","author":"Scharl","year":"2024","journal-title":"J Eur Soc Therapeut Radiol Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0055","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bju.16150","article-title":"F-SHARP: a phase I\/II trial of focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer","volume":"133","author":"Solanki","year":"2024","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0056","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.brachy.2011.09.008","article-title":"American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy","volume":"11","author":"Yamada","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0057","article-title":"American Radium Society appropriate use criteria for the workup and treatment of local intraprostatic recurrence of prostate cancer following definitive radiotherapy","author":"Valle","year":"2024","journal-title":"Eur Urol Oncol."},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0058","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13014-021-01839-w","article-title":"Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes","volume":"16","author":"Lewin","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0059","doi-asserted-by":"crossref","first-page":"TPS5120","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5120","article-title":"Veterans Affairs seamless phase II\/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligometastatic prostate cancer (VA STARPORT)","volume":"42","author":"Solanki","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0060","first-page":"41","article-title":"Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET\/CT and multi-parametric MRI","volume":"32","author":"Liu","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.014_bib0061","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2017.08.005","article-title":"Topography of prostate cancer recurrence after radiation therapy: A detailed mapping study of salvage radical prostatectomy specimens","volume":"73","author":"Takeda","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0062","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.juro.2012.02.2571","article-title":"Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy","volume":"188","author":"Leibovici","year":"2012","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0063","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brachy.2016.12.011","article-title":"Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation","volume":"16","author":"Baumann","year":"2017","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0064","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2013.01.027","article-title":"Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes","volume":"86","author":"Chen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.014_bib0065","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00066-017-1157-2","volume":"193","author":"Chatzikonstantinou","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110381","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 gy or two fractions of 13.5 gy: A 9-year update","volume":"198","author":"Hudson","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110426","article-title":"Single-dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer","volume":"199","author":"Hoskin","year":"2024","journal-title":"Radiother Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.014_bib0068","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.014_bib0069","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0070","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1016\/j.prro.2022.05.018","article-title":"A prospective study of Magnetic resonance imaging-guided Focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: Updated results of 30 patients","volume":"12","author":"Corkum","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.014_bib0071","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.prro.2023.05.012","article-title":"A phase 1 trial of focal salvage stereotactic body radiation therapy for radiorecurrent prostate cancer","volume":"13","author":"Patel","year":"2023","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.014_bib0072","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.ijrobp.2024.02.014","article-title":"A phase 1 trial of salvage stereotactic body radiation therapy for radiorecurrent prostate cancer after brachytherapy","volume":"119","author":"Patel","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.semradonc.2025.04.014_bib0073","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.23.01391","article-title":"Salvage reirradiation for locally recurrent prostate cancer: results from a prospective study with 7.2 years of follow-up","volume":"42","author":"Ekanger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0074","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.prro.2023.08.017","article-title":"Monitoring intrafraction motion of the prostate during radiation therapy: suggested practice points from a focused review","volume":"14","author":"Shimomura","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.014_bib0075","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2017.11.020","article-title":"Use of concomitant androgen deprivation therapy in patients treated with early salvage radiotherapy for biochemical recurrence after radical prostatectomy: long-term results from a large, multi-institutional series","volume":"73","author":"Gandaglia","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.014_bib0076","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.014_bib0077","first-page":"1","article-title":"Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients","volume":"27","author":"van Son","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0078","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.ijrobp.2024.07.227","article-title":"Initial results of a multi-institutional phase 1\/2 trial of focal dose-escalated salvage high dose rate brachytherapy for radiorecurrent prostate cancer (F-SHARP)","volume":"120","author":"Solanki","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1094","key":"10.1016\/j.semradonc.2025.04.014_bib0079","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180494","article-title":"Reirradiation for isolated local recurrence of prostate cancer: mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)","volume":"92","author":"Jereczek-Fossa","year":"2019","journal-title":"Br J Radiol"},{"issue":"36","key":"10.1016\/j.semradonc.2025.04.014_bib0080","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: A randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.semradonc.2025.04.014_bib0081","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.3390\/cancers13174339","article-title":"Stereotactic re-irradiation for local recurrence after radical prostatectomy and radiation therapy: A retrospective multicenter study","volume":"13","author":"Perennec","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.014_bib0082","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brachy.2013.11.005","article-title":"A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy","volume":"13","author":"Yamada","year":"2014","journal-title":"Brachytherapy"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:06:20Z","timestamp":1750791980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000426"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.014","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Management of Radiorecurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}